Indication
Inflammatory Disease
9 clinical trials
19 products
2 drugs
Clinical trial
A Phase 1, Double-blind, Single and Multiple-Dose Study of Safety, Tolerability and Pharmacokinetics of Amilo-5MER in Healthy VolunteersStatus: Completed, Estimated PCD: 2021-07-01
Product
amilo-5MERClinical trial
The Effectiveness of Hydroxylated Polymethoxy Flavones Solid Dispersion Incorporated Sodium Carboxymethyl Cellulose Gel With Periodontal Debridement in the Treatment of Periodontitis. Clinical- Biochemical StudyStatus: Not yet recruiting, Estimated PCD: 2023-11-20
Product
chlorhexidineDrug
placeboClinical trial
The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using AbataceptStatus: Active (not recruiting), Estimated PCD: 2025-06-01
Product
Varicella Zoster VaccineClinical trial
Personalized Targeted Therapies in Inflammatory Complex Multi Organ DiseaseStatus: Recruiting, Estimated PCD: 2025-11-01
Product
KineretProduct
HumiraProduct
StelaraProduct
CosentyxProduct
RoactemraDrug
VarlilumabClinical trial
Phase 1 Biodistribution and Pathophysiology Study of 18F-Fluorodeoxysorbitol (18F-FDS)Status: Recruiting, Estimated PCD: 2025-05-31
Product
18F-FDS PET/CTClinical trial
Phase 1 Biodistribution and Pathophysiology Study of 11C-para-aminobenzoic Acid (11C-PABA)Status: Recruiting, Estimated PCD: 2026-11-26
Product
11C-para-aminobenzoic acidProduct
ProbenecidClinical trial
The Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Transplantation in Aging-related Low-grade Inflammation Patients' Pro-inflammatory Cytokines: a Single-group, Open-label, Phase I/II Clinical TrialStatus: Active (not recruiting), Estimated PCD: 2026-01-01
Clinical trial
Antibiotic Prophylaxis in High-Risk Arthroplasty PatientsStatus: , Estimated PCD: 2025-06-01
Product
CephalexinProduct
DoxycyclineProduct
CefadroxilClinical trial
Efficacy and Safety of Comprehensive Treatment in Patients With Inflammation-associated Rapidly-progressive Coronary Artery Disease (IR-CAD): a Self-controlled Cohort StudyStatus: Recruiting, Estimated PCD: 2025-09-01
Product
Immunosuppressive therapyProduct
Supportive therapies